Royalty Pharma plc
RPRX
$39.82
$0.290.72%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 288.22M | 30.18M | 238.35M | 208.21M | 543.99M |
| Total Depreciation and Amortization | 1.28M | 1.38M | -- | -- | -- |
| Total Amortization of Deferred Charges | 6.14M | 5.31M | 5.28M | 5.31M | 5.35M |
| Total Other Non-Cash Items | -424.50M | -449.09M | -412.82M | -299.99M | -618.61M |
| Change in Net Operating Assets | 831.48M | 776.22M | 765.26M | 829.00M | 772.89M |
| Cash from Operations | 702.62M | 363.98M | 596.08M | 742.53M | 703.61M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -226.00K | -74.19M | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -958.09M | -237.79M | 503.92M | -505.59M | -1.19B |
| Cash from Investing | -958.31M | -311.98M | 503.92M | -505.59M | -1.19B |
| Total Debt Issued | 3.23B | -- | -- | 0.00 | 0.00 |
| Total Debt Repaid | -2.28B | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -146.49M | -291.57M | -708.78M | -52.61M | -97.05M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -95.31M | -93.24M | -95.36M | -93.66M | -94.06M |
| Other Financing Activities | -149.94M | -123.00M | -137.16M | -111.70M | -134.40M |
| Cash from Financing | 562.74M | -507.81M | -941.30M | -257.96M | -325.51M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 307.04M | -455.81M | 158.69M | -21.03M | -814.59M |